Sign inJoin waitlistJoin the waitlist

Igor Puzanov

Professor · University at Buffalo School of Medicine

Credentials: · · · · · ·

History

University at Buffalo School of Medicine
Present

University of Texas Southwestern Medical Center
1994–1996
Internal Medicine
1991–1994
Doctor of Medicine
1987–1991

Research

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 2,915 citations
Inhibition of mutated, activated BRAF in metastatic melanoma
New England Journal of Medicine · 2010 · 2,847 citations
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
New England Journal of Medicine · 2012 · 2,234 citations

Jeffrey Sosman
46 papers
Marc Ernstoff
33 papers
Omid Hamid
30 papers
Douglas Johnson
27 papers
Antoni Ribas
20 papers
Michael Atkins
20 papers
Keith Flaherty
18 papers
Stephen Hodi
18 papers
Ryan Sullivan
17 papers · 1 as a fellow
David McDermott
15 papers
KL
Karl Lewis
15 papers
Michael Postow
15 papers

Grants

Roswell Park Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $2.8M · Roswell Park Cancer Institute Corp
1997–2029
Network Lead Academic Participating Site Grant from the Roswell Park Cancer Institute
National Cancer Institute · UG1
PI · $2M · Roswell Park Cancer Institute Corp
2019–2026
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy
National Cancer Institute · P01
Project lead · $2.3M · Roswell Park Cancer Institute Corp
2020–2026
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $37.8K · Vanderbilt University
2005–2007

Clinical trials

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Principal investigator · Terminated · Phase 2
Roswell Park Cancer Institute
2024–2025
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Principal investigator · Terminated · Phase 1, Phase 2
Roswell Park Cancer Institute
2020–2023
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Principal investigator · Active not recruiting
OncoHost Ltd.
2019–2029
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2005